EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes

Aiswarya Puzhakkara Chennas iD, Ignacio Leiva-Escobar iD, Stefan Lars Reckelkamm iD, Birte Holtfreter iD, Thomas Kocher iD, Sebastian-Edgar Baumeister iD, Michael Nolde iD, Zoheir Alayash iD

Journal of Periodontal Research · 2026-06 · 61 (6) · 695-704

DOI: 10.1111/jre.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Periodontal Research, online erschienen am 28.06.2026. Verfasst von Aiswarya Puzhakkara Chennas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Services Research in Dentistry, University of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Antihypertensive Agents, Dental Caries, Chronic Periodontitis, Periodontitis. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Antihypertensive medications are widely prescribed for hypertension, yet evidence regarding their oral health safety remains limited. We aimed to investigate whether genetically proxied pharmacological actions of antihypertensive drug classes influence the risk of periodontitis and dental caries using a two‐sample drug‐target Mendelian randomization framework.

Methods

Genetic instruments were obtained for 12 antihypertensive drug classes using variants within or near target genes associated with systolic blood pressure (SBP) in two genome‐wide association study (GWAS) meta‐analyses: one combining data from the International Consortium of Blood Pressure and UK Biobank, and another additionally including the Million Veteran Program (MVP) and Vanderbilt University's biorepository. Summary statistics for chronic periodontitis were obtained from the MVP GWAS, and for dental caries from the Gene‐Lifestyle Interactions in Dental Endpoints consortium using the decayed, missing, and filled surfaces index. Causal effects were estimated using the inverse‐variance weighted method with Benjamini–Hochberg correction for multiple testing. Colocalization analyses assessed whether drug targets and outcomes shared causal variants.

Results

Genetically proxied diazoxide acting through the KCNJ11 locus was associated with chronic periodontitis after multiple‐testing correction (odds ratio [OR] per 1 mmHg lower SBP: 1.06, 95% confidence interval [CI]: 1.02–1.09), with consistent estimates after excluding variants associated with type 2 diabetes. No other associations were observed. Colocalization analyses provided no evidence of shared causal variants.

Conclusion

We found little evidence that genetically proxied on‐target pharmacological actions of antihypertensive drug classes were associated with periodontitis or dental caries. The diazoxide–periodontitis association should be interpreted with caution, given possible residual pleiotropy at the KCNJ11 locus and the absence of colocalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsDental CariesChronic PeriodontitisPeriodontitisHumansGenome-Wide Association StudyHypertensionMendelian Randomization AnalysisBlood PressureKcnj11 ChannelPotassium Channels, Inwardly RectifyingPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

Mendelian randomization analysisantihypertensive agentsdental cariesperiodontitis

Substanzen

Antihypertensive AgentsKcnj11 ChannelPotassium Channels, Inwardly Rectifying

Autor:innen und Institutionen

  • Institute of Health Services Research in Dentistry, University of Münster, Münster, Germany.
  • Clinic for Periodontology and Conservative Dentistry, University of Münster, Münster, Germany.
  • Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Greifswald, Germany.

ORCID-Profile: Aiswarya Puzhakkara Chennas, Ignacio Leiva-Escobar, Stefan Lars Reckelkamm, Birte Holtfreter, Thomas Kocher, Sebastian-Edgar Baumeister, Michael Nolde, Zoheir Alayash

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Puzhakkara Chennas, A., Leiva-Escobar, I., Reckelkamm, S. L., Holtfreter, B., Kocher, T., Baumeister, S. E., Nolde, M., & Alayash, Z. (2026). Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes. Journal of Periodontal Research, 61(6), 695-704. https://doi.org/10.1111/jre.70143

Vancouver

Puzhakkara Chennas A, Leiva-Escobar I, Reckelkamm SL, Holtfreter B, Kocher T, Baumeister SE, et al. Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes. Journal of Periodontal Research. 2026;61(6):695-704. doi:10.1111/jre.70143

BibTeX
@article{PuzhakkaraChennas2026,
  author = {Puzhakkara Chennas, Aiswarya and Leiva-Escobar, Ignacio and Reckelkamm, Stefan Lars and Holtfreter, Birte and Kocher, Thomas and Baumeister, Sebastian-Edgar and Nolde, Michael and Alayash, Zoheir},
  title = {Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes},
  journal = {Journal of Periodontal Research},
  year = {2026},
  volume = {61},
  number = {6},
  pages = {695--704},
  doi = {10.1111/jre.70143}
}
Kostenlos starten →